Classification and evaluation of the pharmacodynamics of psychotropic drugs by single-lead pharmaco-EEG, EEG mapping and tomography (LORETA).
Utilizing computer-assisted quantitative analyses of human scalp-recorded electroencephalogram (EEG) in combination with certain statistical procedures (quantitative pharmaco-EEG) and mapping techniques (pharmaco-EEG mapping), it is possible to classify psychotropic substances and objectively evaluate their bioavailability at the target organ: the human brain. Specifically, one may determine at an early stage of drug development whether a drug is effective on the central nervous system (CNS) compared with placebo, what its clinical efficacy will be like, at which dosage it acts, when it acts and the equipotent dosages of different galenic formulations. Pharmaco-EEG profiles and maps of neuroleptics, antidepressants, tranquilizers, hypnotics, psychostimulants and nootropics/cognition-enhancing drugs will be described in this paper. Methodological problems, as well as the relationships between acute and chronic drug effects, alterations in normal subjects and patients, CNS effects, therapeutic efficacy and pharmacokinetic and pharmacodynamic data will be discussed. In recent times, imaging of drug effects on the regional brain electrical activity of healthy subjects by means of EEG tomography such as low-resolution electromagnetic tomography (LORETA) has been used for identifying brain areas predominantly involved in psychopharmacological action. This will be demonstrated for the representative drugs of the four main psychopharmacological classes, such as 3 mg haloperidol for neuroleptics, 20 mg citalopram for antidepressants, 2 mg lorazepam for tranquilizers and 20 mg methylphenidate for psychostimulants. LORETA demonstrates that these psychopharmacological classes affect brain structures differently.
Saletu
B
B
Section of Sleep Research and Pharmacopsychiatry, Department of Psychiatry, University of Vienna, Vienna, Austria.
Anderer
P
P
Saletu-Zyhlarz
G M
GM
Arnold
O
O
Pascual-Marqui
R D
RD
D001931:Brain Mapping / Q000379:methods*; D004341:Drug Evaluation / Q000379:methods; D004569:Electroencephalography / Q000187:drug effects* / Q000379:methods; D055590:Electromagnetic Phenomena; D006801:Humans; D011619:Psychotropic Drugs / Q000145:classification* / Q000494:pharmacology*; D014054:Tomography / Q000379:methods
D011619:Psychotropic Drugs